The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2017

Filed:

Nov. 29, 2011
Applicants:

Joseph Krebs, Austin, TX (US);

Paul Morrison, Austin, TX (US);

Jun Wang, Austin, TX (US);

Inventors:

Joseph Krebs, Austin, TX (US);

Paul Morrison, Austin, TX (US);

Jun Wang, Austin, TX (US);

Assignee:

Bioo Scientific Corporation, Austin, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/195 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01); C07K 19/00 (2006.01); C07K 16/40 (2006.01); C12N 9/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/195 (2013.01); C07K 16/00 (2013.01); C07K 16/40 (2013.01); C12N 9/0008 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6043 (2013.01); C07K 2319/00 (2013.01);
Abstract

Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates. These recombinant antigen-carriers are designed to specifically aggregate in vivo after administration into the host; this aggregation greatly enhances immunogenicity and may eliminate the need for the use of chemical adjuvants which cause physical irritation and discomfort to the host.


Find Patent Forward Citations

Loading…